Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Transplantation. 2015 Apr;99(4):668–677. doi: 10.1097/TP.0000000000000561

Figure 2. VEGFR-3 regulates CCL21 tissue expression and gradient.

Figure 2

(A) Naive ear skin sheets stained for LYVE-1 (Cy3), CD31 (DyeLight 488), and CCL21 (Cy5). Original magnification 200×. Bars, 50 μm. (B) Anti-VEGFR-3 (7μg) or control mAb (7μg) injected into pinnae, ears harvested after 6 hours, and skin sheets stained for LYVE-1 (Cy3) and CCL21 (Cy5). Representative staining pattern of LYVE-1 and CCL21 in lymphatics. CCL21 positive area is shown in light green in the third image. LYVE-1+ lymphatics are traced with white dotted line. (C) Same as (B), CCL21 aggregates (left) or CCL21+ area (right) in lymphatics (at least 10 fields/group) measured. Results from 2 mice/group, 10 independent experiments. * p<0.05; n.s., not significant by unpaired t-test.